UG

United-Guardian, Inc. (UG) SWOT Analysis Analysis (2026)

Invetso Score: 6.1/10 — Balanced · Last Updated: 2026-09-01

Monthly Update
Overall Score66.1
Change+0.1

Strengths

Score: 7.3 (Strong)

United-Guardian’s strong capital efficiency, outstanding liquidity, and growth in non-cosmetic segments provide a solid foundation to weather near-term volatility and support future investment.

Weaknesses

Score:

United-Guardian’s dependence on a single distributor, recent sales declines, and limited organic growth avenues restrict its ability to drive sustained expansion without successful diversification.

Opportunities

Score:

Strategic initiatives in pharmaceuticals and new distribution channels offer credible paths to growth, though execution and market recovery are critical for realizing these opportunities.

Threats

Score:

United-Guardian faces elevated risk from customer concentration, regional volatility, and intensifying competition, which could prolong revenue and margin pressure if not addressed.

Overall Score

Score:

United-Guardian’s strong balance sheet and resilient pharmaceutical segment provide stability, but high customer concentration, recent sales declines, and external risks limit near-term upside. The company’s improved liquidity and slightly stronger capital efficiency support a modestly better overall profile, though diversification and execution on growth initiatives remain key to a sustained re-rating.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on United-Guardian, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →